Alkem licenses technology from Harvard to treat ischemic injury and vascular diseases
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Abdomen-pelvis CT is the nation’s highest-volume CT category
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Subscribe To Our Newsletter & Stay Updated